论文部分内容阅读
目的:探讨阿奇霉素对伴有肺炎支原体感染的哮喘发作患儿肺功能的影响。方法:将62例哮喘伴发肺炎支原体感染患儿随机分为观察组和对照组,各31例。在常规治疗基础上观察组给予阿奇霉素治疗,对照组采用红霉素治疗,治疗4个疗程后对两组患儿的症状缓解消失时间、临床疗效、肺功能、外周血白细胞数以及不良反应发生情况进行比较。结果:经治疗,观察组咳嗽消失、气促缓解及肺部哮鸣音消失时间均比对照组短,差异均有统计学意义(P<0.05);观察组治疗总有效率为93.5%(29/31),高于对照组的71.0%(22/31),差异有统计学意义(P<0.05);观察组肺功能改善优于对照组,外周血白细胞计数显著低于治疗前及对照组,差异均有统计学意义(P<0.05);观察组31例患儿中发生胃肠道反应3例,皮疹、丙氨酸氨基转移酶升高及局部疼痛各1例,不良反应发生率为19.4%(6/31),低于对照组的48.4%(15/31),差异有统计学意义(P<0.05)。结论:阿奇霉素能显著缓解哮喘临床症状,改善肺功能,发挥抗感染作用,且不良反应发生率低,安全性较高。
Objective: To investigate the effect of azithromycin on pulmonary function in asthmatic children with mycoplasma pneumoniae infection. Methods: Sixty-two asthmatic children with mycoplasma pneumoniae infection were randomly divided into observation group and control group, with 31 cases in each group. On the basis of routine treatment, the observation group was treated with azithromycin and the control group was treated with erythromycin. The symptom relieved disappearance time, clinical efficacy, lung function, peripheral blood leukocytes and adverse reactions in the two groups after 4 courses of treatment Compare. Results: After treatment, the disappearance of cough, the relief of shortness of breath and the disappearance of lung wheeze in the observation group were shorter than those in the control group (P <0.05). The total effective rate in the observation group was 93.5% (29 / 31), higher than 71.0% (22/31) in the control group, the difference was statistically significant (P <0.05); the improvement of pulmonary function in the observation group was better than that in the control group, the peripheral blood leukocyte count was significantly lower than that in the control group , Respectively (all P <0.05). There were 3 cases of gastrointestinal reaction, 1 case of rash, elevated alanine aminotransferase and 1 case of local pain in 31 cases in the observation group. The incidence of adverse reactions was 19.4% (6/31), which was lower than 48.4% (15/31) in the control group. The difference was statistically significant (P <0.05). Conclusion: Azithromycin can significantly relieve the clinical symptoms of asthma, improve lung function and exert anti-infective effect with low incidence of adverse reactions and high safety.